U.S. markets open in 1 hour 47 minutes

GlycoMimetics, Inc. (GLYC)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.6000-0.0500 (-1.37%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close3.6500
Open3.8500
Bid3.5000 x 800
Ask4.8900 x 1300
Day's Range3.5400 - 3.8590
52 Week Range1.8200 - 6.2900
Volume1,157,799
Avg. Volume419,593
Market Cap172.184M
Beta (5Y Monthly)2.43
PE Ratio (TTM)N/A
EPS (TTM)-1.1260
Earnings DateNov 06, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlycoMimetics to Present at Two Upcoming Virtual Healthcare Investor Conferences
    Business Wire

    GlycoMimetics to Present at Two Upcoming Virtual Healthcare Investor Conferences

    GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that CEO Rachel King plans to present an overview of the company at the upcoming Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17 and the Jefferies Virtual London Healthcare Conference on Thursday, November 19. Both presentations will be available on the Company’s website, under the Investors tab. Details are as follows:

  • GlycoMimetics Inc (GLYC) Q3 2020 Earnings Call Transcript
    Motley Fool

    GlycoMimetics Inc (GLYC) Q3 2020 Earnings Call Transcript

    Good Morning and thank you all for joining GlycoMimetics corporate update conference call. Brian will provide an overview of the company's financial position and we'll then open the call for Q&A. Our Co-Founder and Chief Scientific Officer, Dr. John Magnani will join us in the Q&A to address your questions on the emerging preclinical data.

  • GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2020
    Business Wire

    GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2020

    GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the third quarter ended September 30, 2020, and highlighted recent company events. Cash and cash equivalents at September 30, 2020 were $142.9 million.